Clinical Trial Update: Specified Drug-use Surveillance of Fabhalta Capsules

View source ↗

Summary

Novartis is conducting a specified drug-use surveillance trial of Fabhalta Capsules in people with Paroxysmal nocturnal hemoglobinuria, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Fabhalta Capsules

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Status: RECRUITING